Literature DB >> 23479071

Genetic predisposition to left ventricular hypertrophy and the potential involvement of cystatin-C in untreated hypertension.

Dimitris Tousoulis1, Emmanuel Androulakis, Nikolaos Papageorgiou, Antigoni Miliou, Evaggelos Chatzistamatiou, Evaggelos Oikonomou, George Moustakas, Ioannis Kallikazaros, Christodoulos Stefanadis.   

Abstract

BACKGROUND: The angiotensinogen M235T and aldosterone synthase C-344T gene polymorphisms have been associated with cardiac and structure function. However, these associations in untreated hypertension remain unknown. We examined whether these variants determined both echocardiography indices and the potential associated underlying mechanisms, including cystatin-C and vascular inflammation.
METHODS: The study population consisted of 319 untreated patients and 191 healthy individuals. Polymorphisms were determined by polymerase chain reaction technique. Left cardiac indices of geometry and function were assessed by echocardiography. Cystatin-C, intracellular cell adhesion molecule 1, and vascular cell adhesion molecule 1 levels were measured by enzyme-linked immunosorbent assay, whereas high sensitivity C-reactive protein levels were measured by immunonephelometry.
RESULTS: There was no significant interaction between the angiotensinogen genotypes on left ventricular mass index (LVMI) and diastolic function indices in all study groups. Regarding C-344T polymorphism, TT homozygous hypertensive subjects exhibited higher values of LVMI compared with C allele carriers (P = 0.02) and higher prevalence of concentric hypertrophy (P < 0.001). However, this polymorphism was not associated with variations in left atrial volume and diastolic dysfunction. Cystatin-C levels were correlated with LVMI values (r = 0.22; P = 0.002) and mean E/A ratio (r = -0.24; P < 0.001). Interestingly, a linear increase of LVMI with cyctatin-C quartiles has been revealed (F = 5.01; P < 0.001). Moreover, post hoc tests showed that increased levels of cystatin-C (above 75th percentile) were significantly different between both the first (P = 0.009) and the second quartile (P = 0.02).
CONCLUSIONS: We have shown that C-344T potentially predicts higher values of LVMI and concentric hypertrophy in untreated hypertension, independently of renal function and subclinical inflammation. Increased levels of cystatin-C were correlated with higher LVMI values.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479071     DOI: 10.1093/ajh/hps089

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Transcriptional network analysis for the regulation of left ventricular hypertrophy and microvascular remodeling.

Authors:  Aida Moreno-Moral; Massimiliano Mancini; Giulia D'Amati; Paolo Camici; Enrico Petretto
Journal:  J Cardiovasc Transl Res       Date:  2013-08-09       Impact factor: 4.132

2.  Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy.

Authors:  Yi Shen; Xiaoyi Zhang; Chenguang Li; Xiang Wang; Yong Ye; Jie Yuan; Hui Gong; Yunzeng Zou; Junbo Ge
Journal:  Ann Transl Med       Date:  2020-11

3.  Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C.

Authors:  Emmanuel Androulakis; Nikolaos Papageorgiou; Eirini Lioudaki; Evaggelos Chatzistamatiou; Effimia Zacharia; Ioannis Kallikazaros; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-21       Impact factor: 3.738

4.  Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy.

Authors:  Xin Li; Hang Zhu; Peng Li; Qian Xin; Jie Liu; Wei Zhang; You-Hong Xing; Hao Xue
Journal:  J Geriatr Cardiol       Date:  2013-09       Impact factor: 3.327

5.  Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene.

Authors:  Minyue Jia; Boyun Yang; Zhongyi Li; Huiling Shen; Xiaoxiao Song; Wei Gu
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.